ERBB2 and breast carcinoma: Cardiotoxicity among patients with breast cancer and human epidermal growth factor receptor 2 (HER2) gene amplification, primarily manifested as asymptomatic left ventricular (LV) dysfunction, is a well-known complication of the standard treatment.